AbsTrACT background Prenatal and postnatal paracetamol exposure has been previously associated with asthma development in childhood in Western populations. We explore the association between prenatal and postnatal paracetamol exposure and asthma development in a Central European sample of Czech children, suggesting possible additive effect of the both exposures. Furthermore, since aspirin had been used more widely during study data collection in Central Europe, we also compared asthma development for those exposed to paracetamol and aspirin. Methods We used data from 3329 children born in the 1990s as members of the prospective Czech European Longitudinal Study of Pregnancy and Childhood. Data about prenatal and postnatal paracetamol and aspirin exposure, and potential covariates were obtained from questionnaires completed by mothers. Data about incident asthma were obtained from paediatrician health records. results 60.9% of children received paracetamol only postnatally, 1.5% only prenatally and 4.9% of children were exposed both during pregnancy and infancy. Prevalence of asthma in following population was 5% at 11 years. Being exposed to paracetamol both in prenatal and postnatal period was associated with asthma development (unadjusted OR 1.98, 95% CI 1.02 to 3.87). Being exposed only in the postnatal period was also significantly associated with increased risk of asthma. No association between prenatal exposure only and outcome was found. A higher but non-significant risk of asthma was observed for those whose mothers used paracetamol during pregnancy compared with those who used aspirin. Conclusions The main findings of this prospective birth cohort study add to previous observations linking prenatal and early postnatal paracetamol exposure to asthma development. However, the magnitude of effect is relatively modest, and therefore, we recommend paracetamol to remain the analgesic and antipyretic of choice throughout pregnancy and early childhood.
AbsTrACT background Prenatal and postnatal paracetamol exposure has been previously associated with asthma development in childhood in Western populations. We explore the association between prenatal and postnatal paracetamol exposure and asthma development in a Central European sample of Czech children, suggesting possible additive effect of the both exposures. Furthermore, since aspirin had been used more widely during study data collection in Central Europe, we also compared asthma development for those exposed to paracetamol and aspirin. Methods We used data from 3329 children born in the 1990s as members of the prospective Czech European Longitudinal Study of Pregnancy and Childhood. Data about prenatal and postnatal paracetamol and aspirin exposure, and potential covariates were obtained from questionnaires completed by mothers. Data about incident asthma were obtained from paediatrician health records. results 60.9% of children received paracetamol only postnatally, 1.5% only prenatally and 4.9% of children were exposed both during pregnancy and infancy. Prevalence of asthma in following population was 5% at 11 years. Being exposed to paracetamol both in prenatal and postnatal period was associated with asthma development (unadjusted OR 1.98, 95% CI 1.02 to 3.87). Being exposed only in the postnatal period was also significantly associated with increased risk of asthma. No association between prenatal exposure only and outcome was found. A higher but non-significant risk of asthma was observed for those whose mothers used paracetamol during pregnancy compared with those who used aspirin. Conclusions The main findings of this prospective birth cohort study add to previous observations linking prenatal and early postnatal paracetamol exposure to asthma development. However, the magnitude of effect is relatively modest, and therefore, we recommend paracetamol to remain the analgesic and antipyretic of choice throughout pregnancy and early childhood.
InTroduCTIon
Asthma is one of the most common non-communicable diseases. 1 Asthma-like symptoms affect the quality of life, psychological functioning and the well-being of children and their families. 2 Asthma pathogenesis is attributed to both genetic and environmental factors. 3 Environmental risk factors of asthma development include increasing pollution levels, 4 dietary change 5 and hygiene effects, 6 although the evidence to support these remains controversial. [7] [8] [9] It has also been suggested that asthma might be linked to paracetamol exposure in pregnancy and early life. 10 Paracetamol is a widely used non-steroidal analgesic and antipyretic drug. 11 In the 1990s, when aspirin was found to be associated with Reye's syndrome, 12 it replaced aspirin as the analgesic and antipyretic of first choice for pregnant women. Aspirin, also known as acetylsalicylic acid, has been known to be an effective analgesic and antipyretic drug. Aspirin is a non-steroidal anti-inflammatory drug which inhibits the activity of cyclooxygenase, thereby the synthesis of prostaglandins and thromboxanes. 13 Currently, aspirin is not recommended for pregnant mothers and children <16 years of age because it causes severe side effects such as Reye's syndrome. 14 15 Nowadays paracetamol is the recommended drug for self-medication to relieve higher temperature, pain and other discomforts in pregnant women and young children. Paracetamol has only weak anti-inflammatory properties. The action of paracetamol at a molecular level is unclear, but it is known that paracetamol-induced hypothermia is also accompanied by a reduction in brain prostaglandin concentrations and analgesic effect is linked with modulating of serotonergic system. 16 Previous studies demonstrated an association between prenatal exposure to paracetamol and asthma development. [17] [18] [19] Postnatal exposure to paracetamol has been also found to be associated with higher risk of asthma development. [20] [21] [22] Only one Norwegian study demonstrated an association between a combination of prenatal and postnatal exposures and asthma development, suggesting possible additive effect of both exposures. 23 The habits of self-medication in pregnancy were different in Central Europe in the 1990s, and while almost half of the mothers in the above-mentioned Norwegian study used paracetamol in prenatal period, as our Czech European Longitudinal Study of Pregnancy and Childhood (ELSPAC) study data suggests, only slightly more than 10% did the same in the Czech Republic and aspirin was still used more frequently. So far, there have been no studies from Central or Eastern Europe evaluating the association between prenatal and postnatal paracetamol exposures and asthma development in childhood.
We evaluated the association of prenatal and infant paracetamol exposure with asthma development in Czech children before age 11. To enrich our analysis, we additionally explored the research report association between maternal cold/influenza experience during pregnancy and development of asthma compared with the association between asthma development and paracetamol use while experiencing cold/influenza. Furthermore, since aspirin had been used more widely in pregnancy during the study period, we also compared asthma development for those exposed to paracetamol and aspirin.
MeThods study population
Study data were derived from the Czech part of the ELSPAC study, a prospective birth cohort study carried out in the Czech Republic. The ELSPAC study investigated environmental and other factors affecting the health and development of children from the prenatal period until adulthood. Mothers from the Brno and Znojmo regions of Czechoslovakia (now the Czech Republic) who were expected to deliver baby between 1 March 1991 and 30 June 1992 were selected as the target study population. The participation rate of invited pregnant women was 96%. Pairs of mothers and children were followed mainly by means of health records from maternity hospitals/paediatricians and self-reported questionnaires completed by parents and later on by the children themselves. A total of 4811 mothers completed the first self-reported questionnaire in the 20th week of pregnancy. Current analysis is based on 3329 children with information about prenatal and postnatal paracetamol exposure and health records from paediatricians (children with complete data until the age of 11). Informed consent was obtained from all study participants during each wave of data collection. Additional details about the study have been published earlier. 24 
exposure
Information about paracetamol and aspirin use was obtained from the self-reported questionnaires. Mothers were asked at pregnancy (week 20) how often they had taken paracetamol/ aspirin ('not at all', 'sometimes', 'most days' and 'every day') during pregnancy. Paracetamol was taken frequently ('most days' and 'every day') by <1% of women. Therefore, we combined these categories into a binary variable (exposed to paracetamol yes/no). Subsequently, at ages 6 and 18 months of the children, mothers were asked if they had given their infants paracetamol either from birth or from the age of 6 months. To distinguish between prenatal and postnatal paracetamol exposure, we used the following mutually exclusive exposure categories: 'no exposure', 'prenatal exposure only', 'postnatal exposure only' and 'both exposures'. Prenatal and postnatal exposure was defined according to Magnus et al. 23 A similar procedure was used to assess prenatal aspirin exposure.
outcomes
On the basis of paediatric health records from age 3, 5, 7 and 11 years, we defined a group of those children who had at least one record of paediatrician-diagnosed asthma (coded as J45 or J46 in International Classification of Diseases (ICD)-10, or 493.0, 493.1 or 493.9 in ICD-9) treated by medications. Please see online supplementary table 1.
Covariates used in the analysis
Information on potential covariates (potential confounders and mediators) was collected mainly from self-reported questionnaires completed by mothers and fathers during pregnancy, infancy and childhood. Potential parental covariates included age, education, marital status, parity, asthma history, maternal pre-pregnancy body mass index (BMI) and maternal influenza experience during pregnancy. Potential child characteristics included sex, birth weight and breast feeding in the first six months. Environmental characteristics included dwelling type, pet presence at home, maternal smoking, passive smoking, maternal alcohol consumption and visits kindergarten at 3 years. The distribution of covariates included in regression models is shown in table 1.
statistical analyses
All statistical analyses were carried out using STATA software V.14. First, we performed unadjusted logistic regression to investigate the association between prenatal and early life paracetamol exposure and asthma development in childhood. We subsequently constructed an adjusted logistic regression model including all potential risk factors (table 2) .
Second, a similar model was constructed to evaluate whether cold/influenza experience during pregnancy affects the role of paracetamol use in asthma development confounding asthma development. We constructed four mutually exclusive categories for possible interaction between paracetamol use and cold/ influenza: we divided respondents to those whose mothers used paracetamol but did not experience cold/influenza, those whose mothers did not use paracetamol but experienced cold/influenza, those who did not use paracetamol and did not experience cold/ influenza and those who did use paracetamol and experienced cold/influenza. We then examined the association between asthma development and these four combinations by unadjusted and adjusted logistic regression (table 3) .
Third, since paracetamol and aspirin are used for similar indications, we examined the association between mutually exclusive categories, that is, 'no exposure', 'only paracetamol exposure', 'only aspirin exposure' and 'both paracetamol and aspirin exposure' during pregnancy and asthma development (table 4) .
resulTs
Information about prenatal and postnatal exposure to paracetamol (postnatal exposure up to 18 months) and completed health record about asthma diagnosis was available for a total of 3329 children who were thus included in this analysis. In total, 40% of pregnant mothers were aged 20-25 years, 88% were married and about 3% have had asthma. A comprehensive overview of study subject characteristics is provided in table 1.
The frequency of combined prenatal and postnatal paracetamol exposure is shown in table 2. A total of 32.7% of children were never exposed to paracetamol, neither during pregnancy or up to the age of 18 months, 1.5% were exposed only during pregnancy, 60.9% were exposed only postnatally and 4.9% were exposed both during pregnancy and infancy (up to 18 months).
By the age of 11, 5% of all children had a record of physician-diagnosed asthma. The lowest asthma prevalence (3.7%) was reported for the non-exposed group while the highest asthma prevalence (7.0%) was found in the group with both prenatal and postnatal exposure. Table 2 also shows unadjusted and adjusted ORs of the association between paracetamol exposure and asthma development. Prenatal and postnatal exposure to paracetamol was associated with asthma development (unadjusted OR 1.98, 95% CI 1.02 to 3.87). Postnatal paracetamol exposure was slightly associated with asthma (unadjusted OR 1.54, 95% CI 1.06 to 2.23). No statistically significant relationship was identified in the case of prenatal paracetamol exposure. In the multivariable model, the association between prenatal and postnatal paracetamol exposure and asthma development remained practically unchanged. Factors contributing to asthma included asthma family history, maternal education and pet presence at home during the first six months. In addition, the male gender was also found to contribute to the higher risk of asthma development.
In a further analysis, we compared the risk of prenatal cold/ influenza experience and prenatal paracetamol exposure for asthma development. The results indicated that the risk of Adjusted for mother's age, mother's education, marital status, parity, father's age, mother's asthma history, father's asthma history, pre-pregnancy body mass index, cold/influenza during pregnancy, child gender, birth weight, breastfeeding period, type of house, pet at house, visits kindergarten at the age of 3, mother smoking during pregnancy, passive smoking at age of 3 and mother's alcohol consumption during first trimester.
childhood asthma among mothers who suffered from cold/influenza and used paracetamol was 30% higher than in the case of the non-paracetamol-exposed group of mothers. On the other hand, children of mothers who did not experience cold/influenza but used paracetamol for different indications were at a 42% higher risk of asthma. All of these results are statistically non-significant. No significant changes in ORs and CIs occurred following adjustment (table 3) . Prenatal aspirin exposure was reported for 16% of mothers. Prenatal paracetamol exposure was reported for 6.5% of mothers. A higher risk of asthma was observed for those who used paracetamol during pregnancy compared with those who used aspirin or nothing. However, these associations were not statistically significant (table 4) .
dIsCussIon
In this analysis, we observed a modest association between prenatal and postnatal exposure to paracetamol and asthma development during childhood. Our results also demonstrated a higher risk of asthma among children exposed only in early childhood. No association between exposure and outcome was found among children who were only exposed prenatally.
Similar trends were observed in a Norwegian study which analysed prenatal and postnatal paracetamol exposure using a similar pattern. In the analysis by Magnus et al, 23 relative risks of the association between asthma and paracetamol were 1.17 for prenatal exposure only, 1.27 for postnatal exposure only and 1.26 for both exposures. Moreover, another earlier study examining the association between cumulative (prenatal and postnatal) exposure to paracetamol and asthma development reported a positive association with adjusted OR 1.32% and 95% CI 1.06 to 1.65. 18 Our findings are also largely in accordance with results summarised in a previous meta-analysis focusing on the association between asthma and paracetamol exposure in different periods of child development. 25 26 These two meta-analyses reported ORs 1.15 and 1.28 for prenatal exposure, and 1.39 and 1.47 for postnatal exposure. Following adjustment for potential risk factors, a higher risk of asthma was identified among children with a parental asthma history. Genetic risk factors were reported previously in studies associating prenatal paracetamol exposure and childhood asthma development. 27 Furthermore, gender was found to be a clinically relevant robust confounder. Our findings support previous results showing the incidence and prevalence of asthma have been found to be higher among boys than among girls up to the age of 14. 28 29 Previous findings, however, are not entirely consistent, with a smaller prospective study focusing on potential environmental factors showing opposite results. 30 The induction of asthma by paracetamol is biologically plausible. Paracetamol freely crosses the placenta. The potential mechanism of the toxic effect of paracetamol might manifest itself by depleting antioxidant capacity, 31 thereby increasing the generation of reactive oxygen species that could contribute to asthma-related airway inflammation. 32 On the other hand, childhood asthma is associated with perinatal cold/influenza, which is the most frequent indication for use of paracetamol 33 and prenatal cold/influenza is also a risk factor for childhood asthma development. Therefore, we decided to assess the role of these two potentially distinct influences: maternal paracetamol exposure and cold/influenza experience. Our results demonstrated that prenatal paracetamol exposure is a higher risk for asthma development than exposure to cold/influenza only. However, though our results were not statistically significant, they were in accordance with the results of a previous study which demonstrated statistically significant results. 23 Our comparison of the risk posed by paracetamol and aspirin for asthma development was historically motivated. In the 1990s, these two medications were used by pregnant Czech women in a ratio of 1:2 (table 3) . This fact enabled us to evaluate whether associations with prenatal paracetamol use were specific for this particular analgesic or whether they were associated with prenatal analgesic use generally. Our results indicate weak and statistically non-significant differences between individual groups.
More recent studies demonstrated similar patterns for prenatal analgesic and antipyretic exposure. Two studies recently assessed the association between prenatal exposure to ibuprofen and asthma development and found some elevation of risk of asthma associated with ibuprofen exposure. 18 23 Rebordosa demonstrated that children prenatally exposed to aspirin and ibuprofen had no increased risk of asthma development in childhood. 17 Nevertheless, results from the Avon Longitudinal Study of Parents and Children showed that frequent aspirin use in pregnancy was associated with an increased risk of wheezing, that is, the most common preliminary symptom of asthma, only up to 6 months of age. Adjusted for mother's age, mother's education, marital status, parity, father's age, mother's asthma history, father's asthma history, pre-pregnancy body mass index, cold/influenza during pregnancy, child gender, birth weight, breastfeeding period, type of house, pet at house, visits kindergarten at the age of 3, mother smoking during pregnancy, passive smoking at age of 3 and mother's alcohol consumption during first trimester. 
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research report strengths and limitations
At the beginning of the Czech ELSPAC study, the population from which our cohort was drawn was broadly representative of the entire Czech Republic. 24 Although we included only approximately 70% of original study sample in our analysis, the prevalence of asthma reported in the ELSPAC study was found to be in accordance with the prevalence of asthma in Czech children in the 1990s 35 but these data are lower than the data presented by the International Study of Asthma and Allergies in Childhood for Northern and Eastern Europe (prevalence of asthma in children aged 6-7 years, male 9.9 and female 7.5). 36 From the paracetamol exposure point of view, we excluded 35% of the study population due to a lack of information about prenatal or postnatal paracetamol exposure. Therefore, we cannot rule out the possibility that the exclusion of children without complete information might bias our findings. However, for the adverse effects of paracetamol exposure on asthma development to be misleading, there would have to be a protective effect of equal magnitude in those children who were not included, which seems unlikely, especially because we have replicated the previous findings of another cohort. 23 Study limitations included low number of children in some exposure categories and thus related low analytical power particularly for comparisons with those exposed to paracetamol only in pregnancy and also a lack of detailed information about the indication of prenatal and early infancy paracetamol exposure. The lack of more detailed information regarding the frequency of paracetamol exposure in both examined periods likewise posed a potential limitation. Due to a lack of positive responses, data on the frequency of prenatal paracetamol exposure were reduced to a binary variable (used/did not use paracetamol). Nevertheless, this reclassification is likely random with respect to asthma development because only a few mothers took paracetamol during pregnancy on a daily basis. Due to the prospective nature of the data collection, any misclassification of paracetamol exposure is unlikely to be altered by a child's asthma status. Furthermore, birth weight could act as potential mediators between prenatal exposure to paracetamol and study outcome (and thus the multivariable models should not be adjusted for this variable). While we decided to keep birth weight in the final presented model, the results from the model excluding birth weight were virtually identical to the presented ones.
The main findings of this prospective birth cohort study add to previous findings linking prenatal and early postnatal paracetamol exposure to asthma development. The association, however, was not found to be strong, and the causal relationship could not be confirmed by this study. Thus, we recommend that paracetamol remains the analgesic and antipyretic of choice throughout pregnancy and early childhood, but it should be used at the lowest possible dosage and at the shortest possible time because of association between prenatal paracetamol exposure and many health problems. 37 Similarly, postnatal paracetamol use should be also considered carefully.
What is already known on this subject
► Paracetamol is the analgesic and antipyretic of first choice for today's pregnant women and small babies. ► Published studies showed that prenatal paracetamol exposure was associated with asthma development. ► Postnatal exposure to paracetamol was also found to be associated with higher risk of asthma development, although combination of prenatal and postnatal exposure to paracetamol was only rarely investigated.
What this study adds
► Additive effect of combination of prenatal and postnatal paracetamol exposure leads to higher risk of asthma development in specific population using more aspirin than paracetamol-based drugs. ► Increase in risk of asthma development for those exposed to aspirin is smaller than for those exposed to paracetamol. ► Paracetamol still should remain the analgesic and antipyretic of first choice for pregnant women and small babies but mothers should be better informed to consider every paracetamol use carefully.
